Sanofi (SNY) Short term Debt (2009 - 2025)

Sanofi has disclosed Short term Debt across 17 years of filings, most recently posting $5.1 billion for Q4 2025.

• Short term Debt for Q4 2025 came in at $5.1 billion, up 12.37% year-over-year; the trailing twelve-month figure through Dec 2025 was $5.1 billion (up 12.37% YoY), and the FY2025 annual result was $5.1 billion, up 12.37% from the prior year.
• Short term Debt came in at $5.1 billion for Q4 2025 at Sanofi, down from $8.3 billion in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $9.9 billion in Q2 2024 to a low of $2.2 billion in Q4 2023.
• The 5-year median for Short term Debt is $4.4 billion (2024), against an average of $4.9 billion.
• Across the five-year window, Short term Debt tumbled 48.33% in 2023 and soared 104.41% in 2024, its largest moves.
• Sanofi's Short term Debt stood at $3.6 billion in 2021, then climbed by 16.95% to $4.3 billion in 2022, then slumped by 48.33% to $2.2 billion in 2023, then soared by 104.41% to $4.5 billion in 2024, then gained by 12.37% to $5.1 billion in 2025.
• The last three Short term Debt figures came in at $5.1 billion (Q4 2025), $8.3 billion (Q2 2025), and $4.5 billion (Q4 2024), per Business Quant data.